Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Convertible Debt (2016 - 2024)

Regen BioPharma (RGBP) has disclosed Convertible Debt for 9 consecutive years, with $499880.0 as the latest value for Q2 2024.

  • On a quarterly basis, Convertible Debt changed 0.0% to $499880.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $499880.0, a 0.0% change, with the full-year FY2023 number at $499880.0, down 60.4% from a year prior.
  • Convertible Debt was $499880.0 for Q2 2024 at Regen BioPharma, roughly flat from $499880.0 in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $3.0 million in Q1 2022 to a low of $499880.0 in Q4 2022.
  • A 5-year average of $1.4 million and a median of $1.3 million in 2021 define the central range for Convertible Debt.
  • Peak YoY movement for Convertible Debt: increased 22.97% in 2020, then tumbled 83.27% in 2023.
  • Regen BioPharma's Convertible Debt stood at $2.5 million in 2020, then tumbled by 49.58% to $1.3 million in 2021, then tumbled by 60.4% to $499880.0 in 2022, then changed by 0.0% to $499880.0 in 2023, then changed by 0.0% to $499880.0 in 2024.
  • Per Business Quant, the three most recent readings for RGBP's Convertible Debt are $499880.0 (Q2 2024), $499880.0 (Q1 2024), and $499880.0 (Q4 2023).